RecruitingPhase 3NCT05716880
Ketoanalogues for Muscle Mass Loss in Nephrotic Syndrome
Studying Nephrotic syndrome without extrarenal manifestations
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Military Institute od Medicine National Research Institute
- Principal Investigator
- Anna MatyjekMilitary Institute of Medicine National Research Institute
- Intervention
- Ketosteril(drug)
- Enrollment
- 150 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (1)
- Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine - National Research Institute, Warsaw, Masovian District, Poland
Collaborators
Medical University of Lodz · Medical University of Warsaw
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05716880 on ClinicalTrials.govOther trials for Nephrotic syndrome without extrarenal manifestations
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07267026A Study to Evaluate the Safety, Tolerability and PK of SK-09Consun Pharmaceutical Group
- RECRUITINGPHASE4NCT07219121Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental GlomerulosclerosisTravere Therapeutics, Inc.
- RECRUITINGNANCT06867471Effects of Exogenous Ketosis on Proteinuria and Renal FunctionGødstrup Hospital
- RECRUITINGPHASE2NCT05003986Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesTravere Therapeutics, Inc.
- RECRUITINGNCT01209000Nephrotic Syndrome Study NetworkUniversity of Michigan
- RECRUITINGNCT01094327Proteinuria in Pre and Post TransplantUniversity of Miami
See all trials for Nephrotic syndrome without extrarenal manifestations →